Minimally Invasive Spinal Stabilization with Denosumab before Total Spondylectomy for a Collapsing Lower Lumbar Spinal Giant Cell Tumor by Minato, Keitaro et al.
B one giant cell tumor (GCT) is a distinct,  locally aggressive neoplasm.  Although histologically 
benign,  it is associated with a high local recurrence rate 
and metastatic potential with predilection for the lungs 
[1 , 2].  The tumor most frequently involves the ends of 
long bones in skeletally mature individuals,  and accounts 
for approximately 4% of all primary bone tumors.  Spinal 
GCT is relatively rare,  with an estimated prevalence of 
2-5% of all GCTs [3].
Denosumab is a new treatment option for locally 
advanced or unresectable GCTs.  Although the effect of 
this agent on GCT of long bones has been reported,  its 
effect on spinal GCT,  especially as a preoperative treat-
ment,  remains unclear.  We describe a patient with spinal 
GCT (Enneking stage III),  in which denosumab therapy 
with percutaneous pedicle screw (PPS) stabilization 
shrank and calcified the tumor,  making total en bloc 
spondylectomy (TES) easier and safer.
The patient was informed that data from the case 




A previously healthy 21-year-old man presented 
with progressive back pain followed by right leg pain.  
Although he was initially diagnosed as having lumbar 
disc herniation and had been treated conservatively for 
2 months by an orthopedic medical practitioner,  his 
symptoms gradually worsened.  He was admitted to a 
regional hospital because of his severe symptoms,  and 
MRI findings raised the suspicion of a spinal tumor 
associated with a pathological fracture at the L5 level (he 
had six lumbar vertebrae).  The lesion was diagnosed as 
a GCT based on needle biopsy results,  and he was 
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A 21-year-old man consulted our hospital for treatment of a spinal giant cell tumor (GCT) of Enneking stage 
III.  Lower lumbar-spine tumors and severe spinal canal stenosis are associated with high risk for surgical mor-
bidity.  Stability was temporarily secured with a percutaneous pedicle screw fixation in combination with deno-
sumab,  which shrank the tumor.  Total en bloc spondylectomy was then performed 6 months after initiation of 
denosumab,  and the patient was followed for 3 years.  There was no local recurrence,  and bony fusion was 
obtained.  Minimally invasive surgery and denosumab allowed safer and easier treatment of a collapsing lower 
lumbar extra-compartmental GCT.
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referred to our hospital.
On admission,  the patient could neither walk nor sit 
because of severe low back pain,  right sciatica,  and 
numbness in his right leg.  Physical examination showed 
neither muscle weakness nor deep tendon reflex abnor-
mality; however,  he experienced dysuria.  Laboratory 
examinations were normal.  His dysuria improved sev-
eral days later after admission and bedrest.
A radiograph revealed a decreased height of the L5 
vertebral body,  especially on the left side,  which was 
associated with a “winking owl” sign,  suggesting a patho-
logical fracture.  Computed tomography revealed an 
osteolytic lesion in the L5 vertebral body,  left pedicle,  
and superior articular process (Fig.1A, B).  MRI revealed 
L5 vertebral body involvement and tumor extension to 
the extra-compartmental area,  including the spinal canal 
with severe canal compromise.  Gadolinium enhance-
ment showed a strong contrast effect (Fig. 1C , D).  The 
tumor was classified as 2-9/A-D according to the 
Weinstein-Boriani-Biagini (WBB) classification [4],  as 
type 5 according to the surgical classification of Tomita 
et al.  [5],  and as Enneking stage III.  No evidence of 
other spinal involvement or lung metastasis was found.
Treatment. Although TES was considered the best 
treatment choice,  two concerns were raised regarding 
the procedure.  One was the potential for neurological 
deficit induced by the dissection procedure between the 
ventral side of the dura mater and the tumor,  which 
severely compressed the neural structure.  The other was 
possible tumor dissemination due to rupture of the tumor 
capsule during isolation of the affected vertebra from the 
surrounding tissue,  including the psoas muscles and 
segmental vessels,  because of the lack of the osseous 
barrier.  Therefore,  it was important to shrink the tumor 
before performing TES,  and it was necessary to perform 
preoperative administration of denosumab and arterial 
embolization.
Nevertheless,  because neurological symptoms had 
already appeared,  it was necessary to obtain stability as 
early as possible.  The effect of denosumab or arterial 
embolism would take several months to manifest.  
Therefore,  we decided to insert a PPS to achieve tem-
porary stability without any manipulation of the tumor 
vertebral body (bleeding 10 ml,  time 57 min).  The 
screws were inserted one level above and one level below 
L5.  Because we were planning a TES 6 months later based 
on the recommendations in the report by de Carvalho 
Cavalcante et al.  [6] and the patient was young with 
good bone quality,  we considered that the short fixation 
was sufficient.  After surgery,  he was put on a rigid brace 
until TES.  As an adjunctive therapy to shrink the tumor,  
it was necessary to perform arterial embolization as soon 
as possible.  Radiologists embolized the feeding arteries 
from the bilateral L4 and L5 lumbar segmental arteries 
on the same day as the PPS.
This initial surgery improved his low back and leg 
pain dramatically.  He received denosumab (120 mg 
subcutaneously) monthly and daily supplements of cal-
cium (500 mg) and vitamin D (400 IU) according to the 
protocol of a phase 2 trial (subcutaneous denosumab 
was given every 4 weeks with additional doses on days 8 
and 15 in cycle 1 only) [7].  The course of the effect of 
denosumab was followed by radiography and CT.  
Calcification of the affected vertebra was evident on CT 
at 6 months (Fig. 2A , B),  and we felt that TES would be 
feasible.  An MRI scan obtained before TES revealed 
marked tumor size reduction,  and the tumor was clas-
sified as 2-9/B-C according to the WBB classification 
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Fig. 1　 Preoperative computed tomography scan revealing a pathological compression fracture of the L5 vertebral body and osteolytic lesion 
(A ,B).  Gadolinium-enhanced T1-weighted magnetic resonance image showing marked enhancement and an extra-compartmental 
extension of the tumor with canal occupation (C ,D).
and as type 3 according to the Tomita classification 
(Fig. 2C , D).
Embolization of the bilateral L4 and L5 lumbar seg-
mental arteries was also performed 4 days before TES.  
TES with a combined posterior and anterior approach 
was performed under spinal cord monitoring using 
motor-evoked potentials and somatosensory-evoked 
potentials on the same day.  During the first part of the 
surgery (posterior approach),  we inserted pedicle screws 
2 levels above (L3 , L4) and below (L6 , S1) the affected 
vertebra,  and S2 alar iliac screws.  Although the screws 
inserted in the previous surgery did not loosen,  they 
were replaced by new screws with larger diameter.  We 
cut both L5 pedicles with T-saws according to the Tomita 
technique [8] and removed the lamina and transverse 
process in an en bloc fashion.  The lateral side of the L5 
vertebra was separated as anteriorly as possible from the 
surrounding tissue,  including the segmental vessels and 
psoas muscles.  This procedure was less difficult than 
expected due to the calcification of the lateral wall of the 
vertebra.  Dissection between the ventral side of the dura 
mater and the posterior longitudinal ligament was rela-
tively easy to perform because of the marked reduction 
in tumor size.  Discectomy was also performed.  After 
we placed the patient in the supine position,  we started 
the anterior approach.  A midline incision was made,  
and a transperitoneal approach was used.  Vascular sur-
geons exposed the aorta and the inferior vena cava and 
then dissected and isolated these great vessels from the 
surrounding tissues,  which provided easy access to the 
affected vertebra.  The affected vertebral body was iso-
lated from the psoas muscles and removed en bloc after 
the anterior discectomies of L4/L5 and L5/L6.  Anterior 
reconstruction was performed by inserting an expand-
able cage within the iliac cancellous bone (Fig. 3A , B).  
Data of spinal cord monitoring did not change through-
out the procedures.  The total bleeding was 2,230 ml,  
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Fig. 2　 Computed tomography scan after 6 months of denosumab therapy revealing calcification of the affected vertebra (A ,B).  Gadolinium-
enhanced T1-weighted magnetic resonance image showing shrinkage of the tumor and no canal occupation (C ,D).
A
B
Fig. 3　 Postoperative radiograph revealing posterior instrumentation 
with anterior reconstruction using an expandable cage 
(A ,B).
and the total operating time was 792 min.
The patient’s postoperative course was uneventful,  
and he was discharged 2 weeks postoperatively with no 
neurological deficit.  Although there was no local recur-
rence at the 6-month follow-up,  chest CT showed a lung 
nodule suggestive of lung metastasis,  which was retro-
spectively detected as a very small nodule on preopera-
tive CT.  This nodule appeared to increase in size after 
cessation of denosumab following TES.  Monthly deno-
sumab was restarted and the size of the lesion decreased 
after 6 months of use.  There was neither local recurrence 
nor regrowth of the lung lesion at the 3-year follow-up 
after TES.
Pathological findings. Histopathological examina-
tion of biopsy specimens confirmed the typical morphol-
ogy of bone GCT,  with a uniform mixture of mononu-
clear cells and osteoclast-like giant cells (Fig. 4A).  No 
evidence of aneurysmal bone cyst formation,  i.e.,  so-called 
malignant osteoid or chondroid matrix,  was found.  
Immunohistochemical analysis,  performed according to 
the same procedure as in a previous report [9],  demon-
strated typical negative staining for receptor activator of 
nuclear factor κ-β ligand (RANKL) among the osteo-
clast-like cells with positive staining among the mono-
nuclear cells (Fig. 4B).  The surgical specimen extracted 
after denosumab therapy was characterized by the 
absence of osteoclast-like giant cells,  while new bone 
formation was observed,  indicating a good response to 
denosumab (Fig. 5A).  Staining with RANKL showed 
only rare positivity among the mononuclear stromal 
cells (Fig. 5B).
Discussion
Spinal GCT is relatively rare,  and therefore it lacks an 
established treatment protocol based on strong scientific 
evidence.  According to the literature,  surgery remains 
the preferred treatment method,  and the primary goal 
is complete resection with wide margins in en bloc 
fashion (if possible),  especially for Enneking stage III 
tumors [10].  However,  two conditions,  in addition to 
the anatomical restrictions of the spine,  made en bloc 
resection difficult in our patient.  One was extra-com-
partmental extension,  which made it likely that an 
intralesional procedure would be required due to the 
lack of a firmer osseous barrier.  The other was severe 
compression of the neural structures,  which elevated 
the risk of neurological deficit [11].
Several treatment options other than en bloc resec-
tion were available when our patient was admitted.  
Curettage may offer a less morbid profile in comparison 
with en bloc resection,  but it has been associated with a 
higher recurrence rate,  ranging between 30% and 50% 
[12 , 13].  Several adjuvant therapies have been proposed 
in addition to curettage or intralesional resection of GCT.  
Radiation therapy has been reported to be efficient as 
either an adjuvant or stand-alone treatment.  There have 
been several small case series of successful GCT treat-
ment (83-100% success rate) in the mobile spine with 
subtotal resection followed by radiation therapy [14].  
The main risk of radiation therapy is radiation-induced 
sarcoma,  with an incidence ranging from 11% to 17%,  
which is not negligible,  especially for younger patients 
[15].  Arterial embolization can lead to the reduction or 
stabilization in the size of spinal GCT.  Although it has 
been used as a preoperative treatment to reduce intra-
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Fig. 5　 Histological examination after denosumab treatment.  (A) 
No osteoclast-like giant cells and no diffuse proliferation of short 
spindle-shaped cells arranged in a storiform pattern are observed.  
Woven bone formation is apparent (hematoxylin-eosin staining; bar=  
20 µm).  (B) Rare receptor activator of nuclear factor kappa-β ligand 
(RANKL)-positive mononuclear cells (RANKL-staining; bar=20 µm).
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Fig. 4　 Histological examination before denosumab treatment.  (A) 
Numerous uniformly spaced,  giant cells,  consistent with 
giant cell tumors (hematoxylin-eosin staining; bar=20 µm).  
(B) Receptor activator of nuclear factor kappa-β ligand 
(RANKL)-positive mononuclear stromal cells surrounding 
osteoclast-like giant cells (RANKL staining; bar=20 µm).
operative blood loss and as a stand-alone treatment for 
inoperable GCT or cases with a high risk of morbidity 
[16],  its efficacy as preoperative adjuvant therapy for 
Enneking stage III may be insufficient [17 , 18].  Over the 
past decade,  some experience with systemic bisphos-
phonate therapy for GCT was reported [19].  It was used 
as postoperative adjuvant therapy,  especially in patients 
with inadequate resection,  resulting in reduction of the 
recurrence rate.  However,  this therapy also has some 
side effects,  especially with long-term use,  including 
osteonecrosis of the jaw,  atypical subtrochanteric and 
diaphyseal femoral fractures,  and esophageal cancer 
[20 , 21].
Denosumab is a fully human monoclonal antibody of 
RANKL.  Because neoplastic stromal cells express high 
concentrations of RANKL,  which activate RANK-positive 
osteoclastic giant cells,  denosumab can prevent bone 
destruction by inhibiting RANK-RANKL interactions [22].  
Several lines of evidence suggest the efficacy of denos-
umab in GCT.  Thomas et al.  reported on 35 patients with 
unresectable or recurrent GCT of the spine or extremities.  
Of these,  30 achieved favorable histological or radio-
logical responses within 6 months after beginning deno-
sumab therapy [23].  Chawla et al.  also demonstrated that 
denosumab controlled unresectable GCT in 96% (163/ 
169) of patients,  including 21 lesions of the mobile spine 
[7].  In addition,  they noted that,  among 100 patients 
with surgically resectable GCT in whom surgery was 
expected to be associated with severe morbidity,  surgery 
was not performed in 74% of the patients,  and 62% of 
the patients who did undergo surgery experienced less 
morbidity after the procedure than was expected.  The 
latter observation is extremely important for surgeons 
who plan invasive and risky surgery,  including en bloc 
spondylectomy in the lower lumbar spine with Enneking 
stage III.
Specifically,  for GCT in the mobile spine,  Goldschlager 
et al.  clearly demonstrated the efficacy of preoperative 
denosumab therapy (for 145-392 days),  followed by 
piecemeal or en bloc resection in 4 patients [24].  They 
observed a reduction in size (10-40%) and calcification 
of the tumors induced by denosumab therapy.  This made 
the surgeries safe and more effective.  In our case,  we 
initially treated the patient with embolization and stabi-
lization with a percutaneous pedicle screw system to 
resolve his severe pain and impending paralysis,  fol-
lowed by 6 months of treatment with denosumab for 
subsequent en bloc spondylectomy.  As Goldschlager et 
al.  described,  the tumor shrank significantly and was 
calcified.  De Carvalho Cavalcante et al.  also reported a 
patient with L4 GCT who was successfully treated with 
en bloc spondylectomy after denosumab treatment [6].  
Yokogawa et al.  reported 25 cases of Enneking stage III 
spinal giant cell tumor,  one of which was treated with 
preoperative denosumab [25].  These reports and ours 
strongly suggest that preoperative denosumab therapy is 
effective.
In the histologic report of a phase 2 study of denos-
umab for bone GCT,  all 20 patients showed a decrease 
in the giant cell concentration by ≥ 90%,  and 65% of 
samples showed a marked increase in dense fibro-osse-
ous tissue and/or new bone [26].  In our case,  the histo-
logic comparison of specimens obtained before and after 
denosumab treatment revealed that the typical structure 
of GCT had considerably changed.  The GCT,  RANKL-
positive proliferative densely cellular stromal cells,  and 
osteoclast-like giant cells were changed after denosumab 
treatment.  Variable amounts of collagenous stroma were 
present between the interweaving fascicles of spindle 
cells,  and the new bone showed only focal RANKL 
positivity.  Osteoclast-like cells were rarely detectable.  
This indicates that denosumab not only restrains the 
bone resorption of GCT,  but also facilitates new bone 
remodeling.
Although denosumab may change the treatment 
paradigm of GCT,  surgery will remain the mainstay for 
resectable GCT.  Since the appropriate duration of 
denosumab as stand-alone therapy is yet to be deter-
mined and a rapid recurrence after the cessation of 
long-term denosumab therapy has been reported,  the 
use of denosumab as stand-alone therapy may tend to 
be prolonged,  and thus may give rise to various compli-
cations,  including osteonecrosis of the jaw and atypical 
femoral fracture [27 , 28].  These complications have 
been reported among patients with osteoporosis who 
used much lower doses of denosumab.  Therefore,  the 
current indications of denosumab therapy as conserva-
tive treatment are unresectable GCT,  such as recurrent 
GCT and GCT in the upper cervical spine or GCT in 
which surgery is likely to result in severe morbidity,  
such as GCT with sacral location.
Although there have been several reports regarding 
denosumab use as a preoperative treatment,  concomitant 
temporary stabilization using a percutaneous pedicle 
screw system before TES has not been reported.  Temporary 
stabilization is considered to be important to prevent 
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malalignment and vertebral collapse,  which may disturb 
the TES procedure due to the expanded transverse 
diameter of the vertebral body and bridging callus for-
mation,  as reported by Yonezawa et al.  [29].  The area 
of stabilization may depend on the vertebral level,  the 
patient’s bone quality and the area of the osteolytic lesion.  
Because one level above and below the affected vertebra 
was sufficient even in our case with lower lumbar level 
involvement and a severely osteolytic lesion,  short sta-
bilization may be adequate irrespective of the vertebral 
level of the tumor in young patients with good bone 
quality.
There are 2 issues to be discussed regarding the 
administration of denosumab.  One is how long preop-
erative use should be.  Dubory et al.  stated that a mini-
mum of 6 months of dosing is required and beyond that 
the effect of denosumab reaches a plateau [30].  Boriani 
et al.  also stated that a minimum of 6 months of preop-
erative administration is required [31].  In our case as 
well,  bone sclerosis was confirmed by CT evaluation at 
6 months,  and TES was considered.  The second issue is 
when to terminate postoperative administration in patients 
with incomplete tumor resection or lung metastasis;  
this question remains unresolved.  Palmerini et al.  eval-
uated long-term efficacy and toxicity of denosumab for 
GCT of bone including spinal GCT [32].  In their study,  
tumor control and clinical benefits were observed in all 
patients undergoing denosumab,  whereas 40% of patients 
discontinuing denosumab had tumor progression.  On 
the other hand,  relatively mild toxicity including dose- 
dependent osteonecrosis of the jaw (ONJ) were found in 
9% (5/54) of patients with a 5-year ONJ-free survival of 
92%.  Therefore,  they proposed to design of treatment 
algorithms that take ONJ into account; for example,  
assessing discontinuation approaches or schedules with 
inferior dose density (3 monthly and 6 monthly).  
Despite their proposal,  the proper timing of the change 
in treatment is still unclear and must be decided on a 
case by case basis.
In conclusion,  denosumab can shrink and calcify the 
spinal GCT,  making surgery safer,  less invasive,  and 
more radical.  The surgical outcome will be improved by 
preoperative use of denosumab.  However,  further 
investigation is necessary,  because the reported cases,  
including ours,  have short follow-up periods.
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